Basis of Presentation and Liquidity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Jul. 09, 2019	May 22, 2019	May 15, 2019	Sep. 05, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jan. 02, 2019
Reverse split of common stock	The Company effected a reverse stock split, in which every nine shares of its common stock issued and outstanding immediately prior to the effective time, which was 5:30 p.m. ET on July 9, 2019, were combined into one share of common stock.	1-for-9 reverse stock split
Reverse stock split		$ 5.58
Noncontrolling interest, description									Outside shareholders' interest in SRP of 37.5% is shown on the condensed consolidated balance sheet as noncontrolling interest.
Accumulated deficit					$ (127,188)				$ (127,188)		$ (124,153)
Available for secured revolving credit facility					1,000				1,000
Right-of-use assets					1,165				1,165
Lease liabilities					1,207				1,207
Allowance for doubtful accounts receivable					29				29		15
Provision for bad debt expense					19				19	$ 21
Write-offs of accounts receivable									5
Sales returns and allowances
Depreciation expense					4	8	7		20	22
Cost of goods sold, depreciation					$ 4				$ 10
ASC 842 [Member]
Right-of-use assets												$ 613
Deferred rent liability												8
Lease liabilities												$ 621
Private Placement [Member]
Number of shares sold in common stock, shares			493,827
Number of common stock shares sold, value			$ 1,992
Private Placement [Member] | Specialty Renal Products, Inc. [Member]
Number of common stock shares sold, value				$ 3,000
Private Placement [Member] | Specialty Renal Products, Inc. [Member] | Minority Interest Ownership [Member]
Noncontrolling interest, percentage				37.50%